Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The practical use of digitals.

North Carolina medical journal·2010
Same author

Treatment of the cardiac arrhythmias.

North Carolina medical journal·2010
Same author

Recent advances in the treatment of cardiovascular disease.

North Carolina medical journal·2010
Same author

The treatment of congestive heart failure.

North Carolina medical journal·2010
Same author

AUGMENTATION OF THE EXTRACARDIAC ANASTOMOSES OF THE CORONARY ARTERIES THROUGH PERICARDIAL ADHESIONS.

The Journal of experimental medicine·2009
Same author

Physician assessment of patient motivation: influence on disposition for follow-up care.

American journal of preventive medicine·1992
Same journal

Patient-, Provider-, and Area-Level Factors Associated with Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis in North Carolina.

North Carolina medical journal·2026
Same journal

Trends in Non-Emergency Medical Transportation During Medicaid Transformation in North Carolina.

North Carolina medical journal·2026
Same journal

Prevalence and Risk Factors for Suicidal Ideation and Attempts Among Black LGBTQ+ Young Adults.

North Carolina medical journal·2026
Same journal

Being There: Presence, Trust, and Rural Health in North Carolina.

North Carolina medical journal·2026
Same journal

Childcare as Workforce Infrastructure: A Practical Strategy For North Carolina's Health System.

North Carolina medical journal·2026
Same journal

Pregnancy Medicaid in North Carolina: An Interview with Maternal and Child Health Professional Jessica Beach.

North Carolina medical journal·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Coronary Angiography During Ex-Situ Heart Perfusion in a Porcine Model
06:25

Coronary Angiography During Ex-Situ Heart Perfusion in a Porcine Model

Published on: July 12, 2024

The cardiac glycosides

R A BROOME, E S ORGAIN

    North Carolina Medical Journal
    |October 29, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    Keywords:
    GLUCOSIDES

    More Related Videos

    High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
    14:03

    High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

    Published on: March 24, 2023

    Related Experiment Videos

    Last Updated: Jun 7, 2026

    Coronary Angiography During Ex-Situ Heart Perfusion in a Porcine Model
    06:25

    Coronary Angiography During Ex-Situ Heart Perfusion in a Porcine Model

    Published on: July 12, 2024

    High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
    14:03

    High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

    Published on: March 24, 2023